Formulation-optimization of solid lipid nanocarrier system of STAT3 inhibitor to improve its activity in triple negative breast cancer cells

References

• Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363:1938–1948.
   PubMed Web of Science ®Google Scholar
• Hudis CA, Gianni L. Triple-negative breast cancer: an unmet medical need. Oncologist. 2011;16:1–11.
   PubMed Web of Science ®Google Scholar
• Xiong A, Yang Z, Shen Y, et al. Transcription factor STAT3 as a novel molecular target for cancer prevention. Cancers. 2014;6:926–957.
   PubMed Web of Science ®Google Scholar
• Pindiprolu SKSS, Krishnamurthy PT, Chintamaneni PK. Pharmacological targets of breast cancer stem cells: a review. Naunyn-Schmiedeberg's Arch Pharmacol. 2018;391:463–479.
   Google Scholar
• Li R, You S, Hu Z, et al. Inhibition of STAT3 by niclosamide synergizes with erlotinib against head and neck cancer. PloS One 2013;8:e74670.
   PubMed Web of Science ®Google Scholar
• Liu J, Chen X, Ward T, et al. Niclosamide inhibits epithelial-mesenchymal transition and tumor growth in lapatinib-resistant human epidermal growth factor receptor 2-positive breast cancer. Int J Biochem Cell Biol. 2016;71:12–23.
   PubMed Web of Science ®Google Scholar
• Liu J, Chen X, Ward T, et al. Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer. Tumor Biol. 2016;37:9825–9835.
   Google Scholar
• Pindiprolu SKSS, Krishnamurthy PT, Chintamaneni PK, et al. Nanocarrier based approaches for targeting breast cancer stem cells. Artif Cells Nanomed Biotechnol. 2018;46:885–898.
   PubMed Web of Science ®Google Scholar
• Liu J, Chen X, Ward T, et al. Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer. Tumor Biol. 2016;37:9825–9835.
   PubMedGoogle Scholar
• Yin L, Gao Y, Zhang X, et al. Niclosamide sensitizes triple-negative breast cancer cells to ionizing radiation in association with the inhibition of Wnt/β-catenin signaling. Oncotarget 2016;7:42126.
   PubMedGoogle Scholar
• Li Y, Li P-K, Roberts MJ, et al. Multi-targeted therapy of cancer by niclosamide: a new application for an old drug. Cancer Lett. 2014;349:8–14.
   PubMed Web of Science ®Google Scholar
• Misra SK, Jensen TW, Pan D. Enriched inhibition of cancer and stem-like cancer cells via STAT-3 modulating niclocelles. Nanoscale. 2015;7:7127–7132.
   PubMed Web of Science ®Google Scholar
• Doane T, Burda C. Noncovalent intracellular drug delivery of hydrophobic drugs on Au NPs. In: Nanomaterial interfaces in biology. Totowa, NJ: Humana Press; 2013. p. 251–260.
   Google Scholar
• Ferris DP, Lu J, Gothard C, et al. Synthesis of biomolecule‐modified mesoporous silica nanoparticles for targeted hydrophobic drug delivery to cancer cells. Small. 2011;7:1816–1826.
   PubMed Web of Science ®Google Scholar
• Peer D, Karp JM, Hong S, et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2:751–760.
   PubMed Web of Science ®Google Scholar
• Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev. 2011;63:131–135.
   PubMed Web of Science ®Google Scholar
• Sahay G, Alakhova DY, Kabanov AV. Endocytosis of nanomedicines. J Control Release 2010;145:182–195.
   PubMed Web of Science ®Google Scholar
• Harush-Frenkel O, Debotton N, Benita S, et al. Targeting of nanoparticles to the clathrin-mediated endocytic pathway. Biochem Biophys Res Commun. 2007;353:26–32.
   PubMed Web of Science ®Google Scholar
• Harush-Frenkel O, Rozentur E, Benita S, et al. Surface charge of nanoparticles determines their endocytic and transcytotic pathway in polarized MDCK cells. Biomacromolecules. 2008;9:435–443.
   PubMed Web of Science ®Google Scholar
• Huang J, Si L, Jiang L, et al. Effect of pluronic F68 block copolymer on P-glycoprotein transport and CYP3A4 metabolism. Int J Pharm. 2008;356:351–353.
   PubMed Web of Science ®Google Scholar
• Alakhova DY, Kabanov AV. Pluronics and MDR reversal: an update. Mol Pharm. 2014;11:2566–2578.
   PubMed Web of Science ®Google Scholar
• Chowdhury P, Nagesh PK, Kumar S, et al. Pluronic nanotechnology for overcoming drug resistance. In: Bioactivity of engineered nanoparticles. Singapore: Springer; 2017. p. 207–237.
   Google Scholar
• Pandita D, Ahuja A, Lather V, et al. Development, characterization and in vitro assessement of stearylamine-based lipid nanoparticles of paclitaxel. Die Pharmazie – Int J Pharm Sci. 2011;66:171–177.
   Google Scholar
• Dhaundiyal A, Jena SK, Samal SK, et al. Alpha‐lipoic acid–stearylamine conjugate‐based solid lipid nanoparticles for tamoxifen delivery: formulation, optimization, in‐vivo pharmacokinetic and hepatotoxicity study. J Pharm Pharmacol. 2016;68:1535–1550.
   PubMed Web of Science ®Google Scholar
• Siddhartha VT, Pindiprolu SKSS, Chintamaneni PK, et al. RAGE receptor targeted bioconjuguate lipid nanoparticles of diallyl disulfide for improved apoptotic activity in triple negative breast cancer: in vitro studies. Artif Cells Nanomed Biotechnol. 2018;46:387–397.
   PubMed Web of Science ®Google Scholar
• Talluri SV, Kuppusamy G, Karri VVSR, et al. Application of quality-by-design approach to optimize diallyl disulfide-loaded solid lipid nanoparticles. Artif Cells Nanomed Biotechnol. 2017;45:474–488.
   PubMed Web of Science ®Google Scholar
• Talluri S, Pindiprolu S, Janarthanam R, et al. Development and efficacy evaluation of smart nanocarriers for targeting breast cancers. Eur J Cancer. 2016;57:S122.
   Google Scholar
• Chen R, Wang S, Zhang J, et al. Aloe-emodin loaded solid lipid nanoparticles: formulation design and in vitro anti-cancer study. Drug Deliv. 2015;22:666–674.
   PubMed Web of Science ®Google Scholar
• Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 1989;49:6449–6465.
   PubMed Web of Science ®Google Scholar
• Li X, Ding R, Han Z, et al. Targeting of cell cycle and let-7a/STAT3 pathway by niclosamide inhibits proliferation, migration and invasion in oral squamous cell carcinoma cells. Biomed Pharmacother. 2017;96:434–442.
   PubMed Web of Science ®Google Scholar
• Duronio RJ, Xiong Y. Signaling pathways that control cell proliferation. Cold Spring Harb Perspect Biol. 2013;5:a008904.
   PubMed Web of Science ®Google Scholar
• Eray M, Mättö M, Kaartinen M, et al. Flow cytometric analysis of apoptotic subpopulations with a combination of Annexin V‐FITC, propidium iodide, and SYTO 17. Cytometry Part A. 2001;43:134–142.
   Web of Science ®Google Scholar
• Kim S-Y, Kang JW, Song X, et al. Role of the IL-6-JAK1-STAT3-Oct-4 pathway in the conversion of non-stem cancer cells into cancer stem-like cells. Cell Signal. 2013;25:961–969.
   PubMed Web of Science ®Google Scholar
• Grandis JR, Drenning SD, Chakraborty A, et al. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth in vitro. J Clin Invest. 1998;102:1385.
   PubMed Web of Science ®Google Scholar